Associate Professor
Medical University of Vienna, Department of Cardiology
Vienna, AUSTRIA, Wien, Austria
Jolanta Siller-Matula, MD PhD, is an Associate Professor in the Department of Cardiology at the Medical University of Vienna, Austria. She is an interventional cardiologist specialising in coronary and structural cardiac interventions. Her publications (>180 peer-reviewed articles; citations>8000; h-index: 46) have added to a debate in the cardiology community surrounding the efficacy and safety of antithrombotic agents in interventional cardiology. She is a leader of I-COMET research team (www.icomet.science) with a current focus on stratified approaches aiming at optimizing outcomes for CAD and after TAVR. She is also a recognised speaker and lecturer and gave more than 150 international and national lectures on conferences covering the topic of thrombosis and interventional cardiology.
Saturday, February 25, 2023
10:16 AM – 10:30 AM ET
Disclosure(s): AOP: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Biosensors: Speakers' Bureau (Terminated, February 8, 2023); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Boston Scientific: Speakers' Bureau (Ongoing); Chiesi: Grants/Research Support Recipient (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Daiichi Sankyo: Speakers' Bureau (Ongoing); P&F GmbH: Consultant/Advisory Board (Terminated, February 8, 2023); Pfizer-Bristol Myers Squibb alliance: Speakers' Bureau (Ongoing)
Saturday, February 25, 2023
11:10 AM – 11:30 AM ET
Disclosure(s): AOP: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Biosensors: Speakers' Bureau (Terminated, February 8, 2023); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Boston Scientific: Speakers' Bureau (Ongoing); Chiesi: Grants/Research Support Recipient (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Daiichi Sankyo: Speakers' Bureau (Ongoing); P&F GmbH: Consultant/Advisory Board (Terminated, February 8, 2023); Pfizer-Bristol Myers Squibb alliance: Speakers' Bureau (Ongoing)
Saturday, February 25, 2023
3:30 PM – 4:30 PM ET
Disclosure(s): AOP: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Biosensors: Speakers' Bureau (Terminated, February 8, 2023); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Boston Scientific: Speakers' Bureau (Ongoing); Chiesi: Grants/Research Support Recipient (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Daiichi Sankyo: Speakers' Bureau (Ongoing); P&F GmbH: Consultant/Advisory Board (Terminated, February 8, 2023); Pfizer-Bristol Myers Squibb alliance: Speakers' Bureau (Ongoing)
Tuesday, February 28, 2023
10:24 AM – 10:32 AM ET
Disclosure(s): AOP: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Biosensors: Speakers' Bureau (Terminated, February 8, 2023); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Boston Scientific: Speakers' Bureau (Ongoing); Chiesi: Grants/Research Support Recipient (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Daiichi Sankyo: Speakers' Bureau (Ongoing); P&F GmbH: Consultant/Advisory Board (Terminated, February 8, 2023); Pfizer-Bristol Myers Squibb alliance: Speakers' Bureau (Ongoing)